NCODA IMMUNOTHERAPY HUB

Practical Resources for CAR-T Cell Therapy and Bispecific T-Cell Engagers

Clinical education, therapy-specific guidance, and implementation tools for multidisciplinary oncology care teams.

Choose a hub to explore available resources.

HUB 01

Bispecific T-Cell Engager Hub

Practical resources to support implementation of bispecific T-cell engagers across care settings, including step-up dosing, toxicity management, patient education, and workflow support.

• Foundational clinical education and microlearning

• "Up Close" agent-specific resources for FDA-approved bispecific T-cell engager therapies
• Example SOPs and real-world practice documents

HUB 02

CAR-T Cell Therapy Hub

Practical resources supporting CAR-T cell therapy across key stages of care, from referral and apheresis through infusion and post-treatment monitoring.

• Foundations clinical education

• “Up Close” agent-specific resources for FDA-approved CAR-T therapies

• Example SOPs and clinic implementation toolkits

NOW LIVE

COMING SOON

AT A GLANCE

Two approaches. One goal.

Both approaches use T-cells to target cancer, but they differ in how treatment is prepared, delivered and monitored.

BISPECIFIC T-CELL ENGAGERS

CAR-T CELL THERAPY

How it works

A bispecific molecule binds a T-cell target, typically CD3, and a tumor-associated target, bringing the cells into close proximity and activating T-cell–mediated killing.

A patient’s T cells are collected and genetically modified to express a chimeric antigen receptor that recognizes a tumor-associated antigen.

Product

Ready-to-use drug product; does not require individualized cell manufacturing.

Patient-specific cell product; current autologous CAR-T therapies require leukapheresis and individualized manufacturing.

Administration

Repeated dosing; most current products begin with a step-up dosing schedule.

Typically a single CAR-T infusion following lymphodepleting chemotherapy.

Selected safety considerations

CRS, neurologic toxicity including ICANS, infections, and cytopenias; timing and monitoring vary by product.

CRS, neurologic toxicity including ICANS, infections, cytopenias, and other product-specific risks.

Care setting

Inpatient and outpatient settings; monitoring requirements vary by product, indication, patient, and institutional protocol.

Specialized treatment programs with coordinated referral and shared-care pathways.

General educational overview. Requirements, monitoring, and risks vary by product and indication. Refer to current prescribing information and institutional protocols.

WHAT YOU'LL FIND

Built for multidisciplinary oncology teams

Each hub brings together clinical education, therapy-specific guidance, and practical tools to support real-world implementation.

Advancing immunotherapy, together.

Start with the hub that fits your practice today — and check back as NCODA continues to expand its immunotherapy resources.

→

→